This episode explores how precision medicine is transforming ovarian cancer care. The discussion covers the challenges of treating advanced and platinum-resistant ovarian cancer, recent advances in targeted therapies and immunotherapy, and the growing impact of biomarker-driven treatment selection. The speakers also examine the role of companion diagnostics, particularly PD-L1 and FRα testing, and how these tools are helping clinicians personalize treatment and expand options for patients. Dr. Brooke Howitt is a gynecologic and sarcoma pathologist at Stanford University whose clinical and research interests focus on gynecologic neoplasms, including the molecular alterations that influence diagnosis, classification, and biomarker-driven patient care. Our second guest, Dr. Bradley Monk, is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute. He has led and contributed to numerous practice-changing clinical trials in gynecologic cancers and is widely recognized for his work advancing precision medicine and novel therapies for women with gynecologic malignancies. This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay. For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent’s CDx Digital Education Portal today: https://bit.ly/3EETZ9t The “Dialogues in CDx” podcast can also be found on Spotify and on Apple Podcasts. D0151976_1.00

 5090      12